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Background:  Preclinical  drug  vs. food  choice  is  an emerging  group  of drug  self-administration  procedures
that have shown  predictive  validity  to clinical  drug  addiction.  Emerging  data  suggest  that  serotonin
(5-HT)2A receptors  modulate  mesolimbic  dopamine  function,  such  that  5-HT2A antagonists  blunt  the
abuse-related  neurochemical  effects  of monoamine  transporter  substrates,  such  as  amphetamine  or
methamphetamine.  Whether  subchronic  5-HT2A antagonist  treatment  attenuates  methamphetamine
reinforcement  in any  preclinical  drug  self-administration  procedure  is  unknown.  The  study  aim  was
therefore  to  determine  7-day  treatment  effects  with  the  5-HT2A inverse  agonist/antagonist  pimavanserin
on  methamphetamine  vs. food  choice  in  monkeys.
Methods: Behavior  was  maintained  under  a concurrent  schedule  of  food  delivery  (1 g pellets,  ﬁxed-
ratio  100  schedule)  and  intravenous  methamphetamine  injections  (0–0.32  mg/kg/injection,  ﬁxed-ratio
10  schedule)  in  male  rhesus  monkeys  (n  =  3).  Methamphetamine  choice  dose-effect  functions  were
determined  daily  before  and  during  7-day  repeated  pimavanserin  (1.0–10  mg/kg/day,  intramuscular)
treatment  periods.
Results: Under  control  conditions,  increasing  methamphetamine  doses  resulted  in  a  corresponding
increase  in methamphetamine  vs. food  choice.  Repeated  pimavanserin  administration  failed  to  atten-
uate  methamphetamine  choice  and  produce  a reciprocal  increase  in  food  choice  in  any monkey  up to
doses  (3.2–10  mg/kg)  that  suppressed  rates  of  operant  responding  primarily  during  components  where
behavior  was  maintained  by  food  pellets.
Conclusions:  Repeated  5-HT2A receptor  inverse  agonist/antagonist  treatment  did not  attenuate  metham-
phetamine  reinforcement  under  a concurrent  schedule  of  intravenous  methamphetamine  and  food
presentation  in nonhuman  primates.  Overall,  these  results  do not  support  the  therapeutic  potential  of
5-HT2A inverse  agonists/antagonists  as  candidate  medications  for methamphetamine  addiction.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Methamphetamine addiction continues to be an insidious and
lobal public health problem for which there are no efﬁcacious
harmacological or behavioral treatment strategies (Brensilver
t al., 2013; Carson and Taylor, 2014). Speciﬁcally, the United
tates Drug Enforcement Agency (DEA) reported that metham-
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376-8716/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).phetamine was the second most nationally identiﬁed illicit
substance, only behind cannabis (DEA, 2015). Moreover, metham-
phetamine use disorder accounted for the majority of global
persons entering treatment for drug use (UNODC, 2015). In sum-
mary, these epidemiological data support the need for preclinical
research to improve our understanding of the neuropharmaco-
logical mechanisms involved in methamphetamine reinforcement.
This improved mechanistic understanding should facilitate the
development of clinically effective strategies to treat metham-
phetamine addiction.
Previous studies have implicated a role of serotonin (5-
HT)2A receptors in the abuse-related neurochemical and behav-
ioral effects of amphetamine or methamphetamine. For exam-
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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le, pretreatment with the 5-HT2A antagonist SR46349-B or
100,907 attenuated amphetamine-induced increases in extracel-
ular dopamine (DA) levels in the striatum and nucleus accumbens
f rodents (Auclair et al., 2004; Porras et al., 2002) and in the caudate
ucleus of nonhuman primates (Murnane et al., 2013a), respec-
ively. Consistent with these neurochemical results, pretreatment
ith the 5-HT2A/2C agonist 5-dimethyoxy-4-iodoamphetamine
DOI) enhanced methamphetamine discriminative stimulus effects
Marona-Lewicka and Nichols, 1997; Munzar et al., 2002, 1999),
hereas the 5-HT2A/2C antagonist ketanserin attenuated metham-
hetamine discriminative stimulus effects (Munzar et al., 1999).
lthough these data implicate a potential role of 5-HT2A receptors
n methamphetamine abuse-related effects, there are no published
tudies determining whether 5-HT2A receptors are necessary for
ethamphetamine reinforcement.
The study aim was to determine repeated 5-HT2A inverse
gonist/antagonist pimavanserin treatment effects on metham-
hetamine reinforcement under a methamphetamine vs. food
hoice procedure. A preclinical drug vs. food choice procedure was
tilized to investigate methamphetamine reinforcement mecha-
isms for the following two reasons. First, preclinical drug vs.
ood choice procedures have been predictive of human drug abuse
nd addiction (Ahmed, 2010; Banks and Negus, 2012). Second,
reclinical drug vs. food choice procedures provide a dependent
easure of behavioral allocation that may  be less sensitive to
einforcement-independent rate-altering drug effects produced by
reatment drugs that may  have potential as candidate medica-
ions (Banks et al., 2015). Pimavanserin was selected because it
s more selective for 5-HT2A vs. 5-HT2C receptors than M100,907
Vanover et al., 2006) and has been recently approved by the Food
nd Drug Administration for Parkinson’s disease-induced psychosis
reatment (Cummings et al., 2014; Walsh, 2016). If pimavanserin
ttenuated methamphetamine choice and produced a correspond-
ng increase in food choice, these preclinical results would suggest
-HT2A receptors were necessary for methamphetamine reinforce-
ent and support further research evaluating 5-HT2A receptor
nverse agonists/antagonists as candidate anti-methamphetamine
ddiction medications.
. Methods
.1. Subjects
Studies were conducted in three adult male rhesus mon-
eys (Macaca mulatta) surgically implanted with a double-lumen
atheter (0.76 mm ID × 2.36 mm OD, STI Flow, Morrisville, NC)
nserted into a femoral or jugular vein and who had metham-
hetamine self-administration histories (Banks and Blough, 2015;
chwienteck and Banks, 2015). Monkeys were maintained on a
iet of fresh fruit and food biscuits (Lab Diet High Protein Monkey
iscuits #5045, PMI  Nutrition Inc., St. Louis, MO)  delivered after
he behavioral session. Water was continuously available in the
ousing chamber and a 12 h light-dark cycle was  in effect. Mon-
eys had visual, auditory and olfactory contact with other monkeys
hroughout the study. Operant procedures and foraging toys were
rovided for environmental manipulation and enrichment. Videos
r music was also played daily in animal housing rooms to pro-
ide additional environmental enrichment. Animal research and
aintenance were conducted according to the Guide for the Care
nd Use of Laboratory Animals (National Research Council, 2011).
nimal facilities were licensed by the United States Department of
griculture and accredited by the Association for Assessment and
ccreditation of Laboratory Animal Care. The Institutional Animal
are and Use Committee approved both the research and environ-
ental enrichment protocols.ndence 165 (2016) 260–264 261
2.2. Apparatus
The housing chamber served as the experimental chamber
and was  equipped with a custom operant panel, a pellet dis-
penser (Med Associates, Model ENV-203-1000, St. Albans, VT), and
two syringe pumps (Model PHM-108, Med  Associates). One “self-
administration” pump delivered contingent methamphetamine
injections through one catheter lumen. The second “treatment”
pump delivered a 0.1 mL  noncontingent saline infusion through the
second catheter lumen at a programmed rate of every 20 min  from
1200 each day until 1100 the following morning. The intravenous
catheter was  protected by a customized stainless steel tether and
jacket system (Lomir Biomedical, Malone, NY) that permitted mon-
keys to move freely within the home chamber. Catheter patency
was periodically evaluated by intravenous ketamine (5 mg/kg)
administration through one lumen of the double-lumen catheter.
The catheter was  considered patent if intravenous ketamine admin-
istration produced muscle tone loss within 10 s.
2.3. Methamphetamine vs. food choice procedure
Daily experimental sessions were conducted from 0900 to
1100 h in each monkey’s home chamber as described previ-
ously (Banks and Blough, 2015). The terminal choice procedure
consisted of ﬁve 20 min  components, with a different unit metham-
phetamine dose available during each successive component (0,
0.01, 0.032, 0.1, and 0.32 mg/kg/injection during components 1–5,
respectively). Manipulating the injection volume controlled the
methamphetamine dose (0, 0.03, 0.1, 0.3, and 1.0 mL/injection,
respectively). Components were separated by 5 min timeout
periods. During each component, the left, food-associated key
was transilluminated red, and completion of the FR require-
ment (FR100) resulted in 1 g food pellet delivery. The right,
methamphetamine-associated key was  transilluminated green,
and completion of the FR requirement (FR10) resulted in delivery of
the intravenous unit methamphetamine dose available during that
component. Stimulus lights for the methamphetamine-associated
key were ﬂashed on and off in 3 s cycles, and longer ﬂashes
were associated with larger methamphetamine doses. Monkeys
could complete up to a total of 10 ratio requirements between
the food- and methamphetamine-associated keys. Responding on
either key reset the ratio requirement on the other key. Each ratio
requirement completion initiated a 30 s timeout, during which
all stimulus lights were turned off, and responding had no pro-
grammed consequences. Choice behavior was  considered stable
when the lowest unit methamphetamine dose maintaining greater
than 80% methamphetamine vs. food choice varied by ≤0.5 log units
for 3 consecutive days.
Once methamphetamine vs. food choice was stable, test ses-
sions were conducted to determine 7-day repeated pimavanserin
(1–10 mg/kg, IM)  treatment effects on methamphetamine vs. food
choice. Pimavanserin was  administered between 0755 and 0805 h,
approximately 60 min  before the 0900 h start of the behavioral ses-
sion. Pimavanserin treatment was tested up to doses that decreased
either methamphetamine choice or operant responding. The 3-
day saline infusion period before each test drug treatment was
used as the “baseline.” At the conclusion of each 7-day treatment
period, intramuscular injections were terminated for at least 4 days
and until methamphetamine vs. food choice had returned to pre-
treatment levels. Pimavanserin doses were counterbalanced across
subjects.2.4. Data analysis
The primary dependent measures were (1) percent metham-
phetamine choice, deﬁned as (number of ratios completed on
2 l Dependence 165 (2016) 260–264
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Fig. 1. Effects of 7-day repeated pimavanserin (1.0–3.2 mg/kg, intramuscular) treat-
ment on choice between methamphetamine and food in rhesus monkeys (n = 3).
Abscissae: unit dose methamphetamine in mg/kg/injection. Top ordinate: per-
cent methamphetamine choice. Bottom ordinate: number of ratio requirements
(choices) completed per choice session component. All points represent mean ± SEM
obtained during days 5–7 of each 7-day treatment period. Numbers in parenthe-62 M.L. Banks / Drug and Alcoho
he methamphetamine-associated key ÷ total number of ratios
ompleted)*100 and (2) number of ratio requirements (hereafter
eferred to as “choices”) completed. The last 3-day mean of each
xperimental condition for each monkey for each dependent mea-
ure was then plotted as a function of unit methamphetamine dose
uring the behavioral session. Results were analyzed using a lin-
ar mixed-effects analysis with unit methamphetamine dose and
imavanserin dose as the ﬁxed main effects and subjects as the
andom effect. Post-hoc comparisons against baseline conditions
ithin a given methamphetamine dose were performed using the
unnett’s test following a signiﬁcant main effect of pimavanserin
ose or methamphetamine dose × pimavanserin dose interaction.
he criterion for signiﬁcance was set a priori at the 95% conﬁdence
evel (p < 0.05). All analyses were conducted using JMP  Pro 12.2,
AS, Cary, NC.
.5. Drugs
(+)-Methamphetamine HCl and pimavanserin l-tartrate were
rovided by the National Institute on Drug Abuse Drug Supply Pro-
ram (Bethesda, MD). All drug doses were expressed as the salt
orms listed above and all drug solutions were passed through a
terile 0.2 m ﬁlter (Millipore, Billerica, MA)  before administration.
. Results
.1. Effects of pimavanserin on methamphetamine vs. food choice
Under control conditions during which saline was  continu-
usly infused through the treatment lumen “baseline”, increasing
ethamphetamine doses resulted in behavioral reallocation away
rom the food-associated key and towards the methamphetamine-
ssociated key (Fig. 1). Repeated pimavanserin treatment failed
o signiﬁcantly alter either methamphetamine vs. food choice or
hoices completed per component (Fig. 1). Due to individual sub-
ect sensitivity to pimavanserin potency to produce rate-altering
ffects, individual data are shown in Fig. 2. In monkey M1515,
epeated pimavanserin treatment had no effect up to pimavanserin
oses (10 mg/kg) that decreased rates of operant responding
rimarily during components maintained by food. Furthermore,
epeated 10 mg/kg pimavanserin treatment also decreased body
eight in this monkey by more than 1 kg. In both monkey M1516
nd M1523, a pimavanserin dose of 3.2 mg/kg decreased rates of
perant responding to such an extent that larger pimavanserin
oses were not tested.
. Discussion
The study aim was to determine whether repeated 5-HT2A
nverse agonist/antagonist pimavanserin administration decreased
ethamphetamine reinforcement in monkeys. The main ﬁnding
as that pimavanserin did not attenuate methamphetamine choice
nd produce a corresponding increase in food choice in any monkey
p to doses that decreased operant response rates and produced
igniﬁcant weight loss. Overall, the present results do not support
he potential clinical utility of 5-HT2A inverse agonists/antagonists
s anti-methamphetamine addiction medications.
The present behavioral results were inconsistent with previ-
us neurochemical (Auclair et al., 2004; Murnane et al., 2013a;
orras et al., 2002) and behavioral (Munzar et al., 1999) results
emonstrating 5-HT2A antagonists attenuated amphetamine or
ethamphetamine abuse-related effects. There are three potential
easons for these inconsistent results. First, potential species dif-
erences between rats and nonhuman primates in either 5-HT2A or
ethamphetamine neuropharmacology could explain these incon-ses  denote the number of monkeys contributing to that data point if less than the
maximal number of monkeys tested and indicate a component where one or more
monkeys failed to complete at least one ratio requirement.
sistent results. A second potential explanation could be related
to differences in dosing regimens. For example, previous stud-
ies utilized acute dosing regimens whereas the present study
determined 5-HT2A inverse agonist/antagonist effects under a
repeated subchronic dosing regimen. Examination of pimavanserin
treatment days 1–3 did not reveal a rightward shift in the metham-
phetamine choice dose-effect function in any monkey (data not
shown). A third potential explanation could be related to dif-
ferences in experimental dependent measures. Previous studies
determined 5-HT2A antagonist effects on amphetamine-induced
dopamine release in either nucleus accumbens (Auclair et al.,
2004; Porras et al., 2002) or caudate nucleus (Murnane et al.,
2013a) and methamphetamine discriminative stimulus effects
(Munzar et al., 1999); whereas the present study determined
5-HT2A inverse agonist/antagonist effects on methamphetamine
reinforcement. However, repeated pimavanserin treatment effects
on methamphetamine self-administration were consistent with
previous studies evaluating ketanserin and M100,907 acute pre-
treatments on cocaine self-administration (Fantegrossi et al., 2002;
Murnane et al., 2013b). Overall, the present results and the previous
literature highlight the importance of repeated pharmacological
M.L. Banks / Drug and Alcohol Dependence 165 (2016) 260–264 263
Fig. 2. Effects of 7-day repeated pimavanserin (1.0–3.2 mg/kg, intramuscular) treatment on choice between methamphetamine and food in individual rhesus monkeys.
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ompleted per choice session component. All points represent mean ± SEM obtained
nly  tested in M1515. Missing data points indicate that a monkey failed to complet
retreatments and determination of treatment effects on multiple
ependent measures to characterize candidate medication treat-
ent efﬁcacy.
Conceptually, 5-HT2A receptor antagonists represent an
antagonist-like” pharmacotherapeutic approach for metham-
hetamine addiction with the neurobiological aim of blunting
ethamphetamine-induced nucleus accumbens dopamine release
nd corresponding reinforcing effects. The present behavioral
esults suggest this may  not be a therapeutically advantageous
reatment option for methamphetamine addiction. The present
esults are consistent with previous methamphetamine vs. food
hoice studies in nonhuman primates evaluating “antagonist-
ike” pharmacological treatments such as dopamine antagoniststhamphetamine choice. Right ordinates: number of ratio requirements (choices)
g days 5–7 of each 7-day treatment period. 10 mg/kg pimavanserin treatment was
ast one ratio requirement during that component.
PG01037, buspirone, and risperidone or the dopamine D3 par-
tial agonist PG619 (Banks and Blough, 2015; John et al., 2015a,
2015b). Furthermore, both the dopamine partial agonist arip-
iprazole and the dopamine antagonist risperidone have failed
to reduce methamphetamine choice in the human laboratory
(Stoops et al., 2013) or methamphetamine use in clinical trials
(Cofﬁn et al., 2013; Nejtek et al., 2008; Tiihonen et al., 2007).
Moreover, “antagonist-like” approaches have not been successful
pharmacotherapeutic strategies to treat amphetamine-type or
cocaine addictions based on a recent meta-analysis (Kishi et al.,
2013). In summary, we interpret this scientiﬁc literature to suggest
methamphetamine addiction medications development might
beneﬁt from a paradigm shift to novel “agonist-like” therapies that
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oth decrease methamphetamine use and promote more adaptive
ehavior maintained by alternative non-drug reinforcers.
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